We’re raising our price target on Eli Lilly as the obesity-drug boom rolls on
Summary
Financial analysts have increased their valuation target for Eli Lilly. This adjustment reflects the ongoing market expansion of the company's popular treatments for obesity and related conditions.
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.